

Atty. Dkt. No. 01698-02

SEP 15 2003
TECH CENTER 1600/2900

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerd GEISSLINGER et al.
Title: USE OF VERAPAMIL AND
VERAPAMIL DERIVATIVES
FOR PRODUCING
MEDICAMENTS WITH AN
INHIBITING EFFECT ON BETA-
GLUCURONIDASE IN HUMAN
TISSUE

Appl. No.: 09/980,824

Filing Date: 12/07/2001

Examiner: B. Kwon

Art Unit: 1614

AMENDMENT TRANSMITTAL

Mail Stop NON-FEE AMENDMENT
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

[] Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a
previous assertion of Small Entity status.

[] Assertion of Small Entity status is enclosed.

[] The fee required for additional claims is calculated below:

	Claims As Amended		Previously Paid For		Extra Claims Present		Rate		Additional Claims Fee
Total Claims:	11	<input type="checkbox"/>	20	=	0	x	\$18.00	=	\$0.00
Independents:	3	<input type="checkbox"/>	3	=	0	x	\$84.00	=	\$0.00
First presentation of any Multiple Dependent Claims:						+	\$280.00	=	\$0.00

CLAIMS FEE TOTAL: = \$0.00

- ☐ Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$410.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the third month:	\$930.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,450.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,970.00	\$0.00
EXTENSION FEE TOTAL:			\$0.00
<input type="checkbox"/>	Statutory Disclaimer Fee under 37 C.F.R. 1.20(d):	\$110.00	\$0.00
CLAIMS, EXTENSION AND DISCLAIMER FEE TOTAL:			\$0.00
<input type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$0.00
TOTAL FEE:			\$0.00

- ☐ Please charge Deposit Account No. 19-0741 in the amount of \$0.00. A duplicate copy of this transmittal is enclosed.

- ☐ A check in the amount of \$0.00 is enclosed.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date


September 12, 2003

By

Steven M. Reid

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 295-4767
Facsimile: (202) 672-5399

Steven M. Reid, Ph.D.
Representative for Applicant
Registration No. 54,393



Atty. Dkt. No. 016916-0252

Appln. Ser. No. 09/980,824

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerd GEISSLINGER et al.

Title: ***USE OF VERAPAMIL AND VERAPAMIL DERIVATIVES FOR
PRODUCING MEDICAMENTS WITH AN INHIBITING EFFECT ON
BETA-GLUCURONIDASE IN HUMAN TISSUE***

Appl. No.: 09/980,824

Filing Date: 12/07/2001

Examiner: B. Kwon

Art Unit: 1614

AMENDMENT AND REPLY UNDER 37 CFR 1.111

Mail Stop NON-FEE AMENDMENT
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

This communication is responsive to the Non-Final Office Action dated June 12, 2003, concerning the captioned patent application. A response is due by September 12, 2003, thereby making this submission timely filed.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks/Arguments begin on page 4 of this document.

Please amend the application as follows: